Gilead Sciences GILD today announced results of a Phase
2 study (Study 101-09) evaluating idelalisib, an investigational oral
inhibitor of PI3K delta, for the treatment of patients with indolent
non-Hodgkin's lymphoma (iNHL) that is refractory (non-responsive) to
rituximab and to alkylating-agent-containing chemotherapy. In this
study, single-agent treatment with idelalisib achieved an overall
response rate of 57 percent with a median duration of response of 12.5
months. The data were presented today during an oral session at the
Annual Meeting of the American Society of Hematology (ASH) in New
Orleans (Abstract #85).
“It has been more than ten years since a treatment with a novel
mechanism of action has been approved for indolent NHL, underscoring
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in